批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
| 审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2011/10/28 |
ORIG-1(原始申请) |
Approval |
Type 3 - New Dosage Form |
STANDARD
|
|
|
>>>补充申请<<<
| 审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2023/11/28 |
SUPPL-51(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2023/11/09 |
SUPPL-44(补充) |
Approval |
Efficacy-New Indication |
STANDARD
|
|
|
| 2021/04/02 |
SUPPL-37(补充) |
Approval |
Manufacturing (CMC)-Manufacturing Process |
N/A
|
|
|
| 2021/03/22 |
SUPPL-35(补充) |
Approval |
Efficacy-New Indication |
STANDARD
|
|
|
| 2021/01/06 |
SUPPL-36(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2018/11/02 |
SUPPL-30(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2018/04/06 |
SUPPL-9(补充) |
Approval |
Efficacy-New Indication |
STANDARD
|
|
|
| 2017/03/08 |
SUPPL-23(补充) |
Approval |
Labeling-Container/Carton Labels |
STANDARD
|
|
|
| 2016/06/10 |
SUPPL-20(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2016/04/15 |
SUPPL-18(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2016/04/05 |
SUPPL-17(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/12/14 |
SUPPL-19(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2015/10/08 |
SUPPL-16(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/09/11 |
SUPPL-15(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/07/27 |
SUPPL-14(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/05/27 |
SUPPL-12(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2014/12/15 |
SUPPL-10(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2014/12/05 |
SUPPL-5(补充) |
Approval |
Labeling-Package Insert,Labeling-Container/Carton Labels |
STANDARD
|
|
|
| 2014/08/13 |
SUPPL-8(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2014/06/05 |
SUPPL-7(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2014/03/28 |
SUPPL-6(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2013/07/10 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
>>>活性成分:BUPIVACAINE; 剂型/给药途径:INJECTABLE, LIPOSOMAL;INJECTION; 规格:133MG/10ML (13.3MG/ML); 治疗等效代码:AP<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 022496 |
001 |
NDA |
EXPAREL |
BUPIVACAINE |
INJECTABLE, LIPOSOMAL;INJECTION |
133MG/10ML (13.3MG/ML) |
Prescription |
Yes |
Yes |
AP |
2011/10/28
|
PACIRA PHARMS INC |
| 214348 |
001 |
ANDA |
BUPIVACAINE LIPOSOME |
BUPIVACAINE |
INJECTABLE, LIPOSOMAL;INJECTION |
133MG/10ML (13.3MG/ML) |
Discontinued |
No |
No |
AP |
2024/07/01
|
HENGRUI PHARMA |
>>>活性成分:BUPIVACAINE; 剂型/给药途径:INJECTABLE, LIPOSOMAL;INJECTION; 规格:266MG/20ML (13.3MG/ML); 治疗等效代码:AP<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 022496 |
002 |
NDA |
EXPAREL |
BUPIVACAINE |
INJECTABLE, LIPOSOMAL;INJECTION |
266MG/20ML (13.3MG/ML) |
Prescription |
Yes |
Yes |
AP |
2011/10/28
|
PACIRA PHARMS INC |
| 214348 |
002 |
ANDA |
BUPIVACAINE LIPOSOME |
BUPIVACAINE |
INJECTABLE, LIPOSOMAL;INJECTION |
266MG/20ML (13.3MG/ML) |
Discontinued |
No |
No |
AP |
2024/07/01
|
HENGRUI PHARMA |